中珠醫療(600568.SH):與北斗醫院管理公司終止合作成立“腫瘤放療中心”項目
格隆匯1月3日丨中珠醫療(600568.SH)公佈,公司於近日收到全資子公司深圳市一體醫療科技有限公司(“一體醫療”)的告知,一體醫療與潮州市北斗車前草醫院管理服務有限公司(“北斗醫院管理公司”)於2020年1月2日簽署了《合同解除協議書》,終止合作成立“腫瘤放療中心”項目。
上述腫瘤放療中心合作項目已啟動前期建設規劃及設備購置,且已發生投入,項目終止後一體醫療的全部投入由北斗醫院管理公司負責接收。公司此次終止合作事項不會影響公司及子公司的正常經營,不會對公司及子公司當期財務狀況、經營成果產生重大影響。此次簽署解除合作協議後,一體醫療已簽約“腫瘤放療中心”合作項目共計13家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.